SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reported record-high monthly and quarterly delivery numbers, sparking enthusiasm about the company's growth. Community discussions revolve around the significant year-over-year increase in deliveries and the potential impact of new models like Onvo and Firefly. Some investors express optimism about NIO's future, while others focus on its valuation relative to competitors in the EV sector.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around the token's vision of merging cryptocurrency with green culture, emphasizing growth, freedom, and innovation within the digital space. Discussions highlight Weedcoin as more than just a digital currency, but as a symbol of a cultural movement and a key to unlocking future opportunities. The community expresses strong conviction and promotes Weedcoin as a force that shapes the digital landscape.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending after reports of a U.S. government equity stake, signaling strong support for domestic lithium production. The community is buzzing about a potential short squeeze and the stock's long-term prospects, drawing comparisons to government-backed runs of $MP and $INTC. Investors view this as a bullish sign for the company's Thacker Pass project and its role in securing the U.S. lithium supply chain.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as a government shutdown looms, triggering volatility and uncertainty. Community members are debating whether the shutdown is already priced in, with some anticipating a potential dip while others expect a market rally similar to past shutdowns. Overall sentiment is mixed, with both bullish and bearish arguments circulating, focusing on historical patterns and potential economic impacts.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu.X is trending as the community rallies around its strong IRL presence and expanding ecosystem, including Kendu Energy drink and other branded products.  Enthusiasm is high as the holder count approaches 19,000, with community members emphasizing that the project combines a high degree of decentralization with a high share of diamond hand holders and a tireless work ethic.

Aventus Network

Aventus Network ($AVT.X) is trending due to its strong chart setup, real-world partnerships (Vodafone, Heathrow Airport, Polkadot) and potential for a breakout. Community members believe the token is undervalued, highlighting its low market cap and integration with Polkadot as catalysts for significant upside. Traders are closely monitoring volume as a key indicator for potential price movement.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to earnings, with community chatter focused on revenue growth and turnaround efforts despite tariff concerns. Discussions include both bullish and bearish outlooks, with some anticipating a move towards $80 while others foresee a drop. The brand's collaboration with SKIMS and the impact of global factors like China sales and potential government shutdowns are also being closely monitored.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to recent unaudited financial results showing positive EPS, sparking discussions about its low float and potential for a short squeeze. The community is actively watching key resistance levels and anticipating further upward movement. Some traders highlight the possibility of a share offering and caution around the stock's historical volatility and association with Chinese companies.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, creating market uncertainty. The community is debating the potential impact, with some anticipating a pullback while others believe a deal will be reached, leading to a rally. Discussions also involve broader market dynamics, such as the influence of a few mega-cap stocks and end-of-quarter window dressing.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to recent price movement, with community members actively discussing potential breakouts and short squeezes, given the stock's low float. Traders are watching key resistance levels, anticipating further upward momentum if these levels are breached. Some traders are expressing concern over potential pump and dump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boeing (BA) has reportedly submitted remedies to the European Union (EU) in an effort to secure regulatory approval for its planned buyback of Spirit AeroSystems (SPR).According to a Reuters report, citing an update on the European Commission's website, the EU competition regulator has extended the deadline for its decision on the deal to October 14.Last year, Boeing announced it would acquire Spirit Aerosystems in a $4.7 billion deal, which would also see Airbus purchasing the supplier's loss-making, Europe-focused activities.Retail sentiment on <a href="https://stocktwits.com/symbol/BA">Boeing</a> remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of Boeing were up 2% during premarket trading on Tuesday.Reuters noted that the EU is expected to look to seek market input before determining whether to approve Boeing’s proposed remedies or initiate a comprehensive four-month investigation if the commission has serious concerns. Last month, the U.K. antitrust authority gave the deal a green light by clearing it unconditionally.Separately, Reuters reported, citing U.S. Democratic Representative Adam Smith, that a group of U.S. lawmakers discussed a potential agreement with senior Chinese officials that could lead to increased purchases of Boeing aircraft by China. The U.S. Ambassador to China, David Purdue, noted that the deal is "very important to the president," the report added.Shares of Boeing jumped nearly 20% this year and have gained over 36% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nike-is-preparing-for-a-big-launch-this-week/chDhqSXR3Px">Nike Is Preparing For A Big Launch This Week: More Details Inside</a>

A Boeing sign is seen on the exterior of a building.

Boeing Proposes Remedies As It Seeks EU Green Light For Spirit AeroSystems Deal: Report

According to a Reuters report, citing an update on the European Commission's website, the EU competition regulator has extended the deadline for its decision on the deal to October 14.

Equity

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the stock.Hunterbrook <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/dexcom/">said</a> on Thursday that it has a short position on DXCM based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s flagship G7 continuous glucose monitor (CGM) device, “some diabetics are ending up in the ICU — or dead.” Hunterbrook Media is an investigative news outlet.The report stated that DexCom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric,” and the company sold the device anyway. This change was revealed during a surprise inspection by the U.S. Food and Drug Administration (FDA), the report stated.Several company executives left the company amid the FDA’s scrutiny and soaring complaints, the report said, while adding that patients are now returning to the G6 or switching to products from competitors, such as Abbott (ABT).Hunterbrook also stated that it has shared its probe with a senior official from the Health and Human Services (HHS) and requested that the FDA intervene. The firm also said that DexCom didn't respond to their requests for comments. The report named people who died or had to be hospitalized following wrong readings by the G7 device, including Billy Sosbe, who died in June, and Diana Bates Knight, who rushed her 6-year-old to the emergency, after the device misread her blood sugar by hundreds of points.“In Dexcom’s crisis, Abbott may see its chance. Our analysis of FDA data shows Dexcom receives more accuracy complaints than its market share predicts; Abbott receives significantly fewer,” Hunterbrook said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DXCM">DXCM</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_2_14_55_PM_png_eb2477f011.webp" alt="DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>DXCM's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that DexCom has proven technology and is leading in CGM.<stembedurl>https://stocktwits.com/CmonManGiveMeABreak/message/629329227</stembedurl>Another user, however, opined that the FDA might pull the G7 device from the market.<stembedurl>https://stocktwits.com/buddyopalosam/message/629325830</stembedurl>DXCM stock is down by 13% this year and by 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/equity/markets/kalvista-pharmaceuticals-hereditary-angioedema-drug-approved-in-eu-switzerland/chD3BkIR3TW">KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the DexCom logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

DexCom Stock Slumps 10% After Hunterbrook Media Investigation Raises Concerns About Its G7 Device

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that some diabetics died after inaccurate readings from Dexcom’s G7  device.

Hunterbrook Capital said on Thursday that it has a short position in DXCM stock based on Hunterbrook Media’s reporting, which stated that after inaccurate readings from Dexcom’s G7 continuous glucose monitor device, some diabetics are ending up in the ICU or dead.


AMC Entertainment Holdings (AMC) shares jumped 5% during midday trading on Friday after the company announced it would play Taylor Swift’s “The Official Release Party Of A Showgirl” at all its 540 theatre locations and thousands of other movie theatre screens in North America, including Cinemark and Regal in the U.S.Swift’s 12th studio album, The Life of a Showgirl,&nbsp;is set to drop on October 3,&nbsp;and the movie will also be released on the same day.&nbsp;&nbsp;The movie will begin on Friday, October 3, and run through Sunday, October 5. AMC stated that it is approximately an 89-minute theatrical experience, which will include the exclusive world premiere of a music video from the album “The Fate of Ophelia” and behind-the-scenes footage from the music video shoot.Retail sentiment on <a href="https://stocktwits.com/symbol/AMC">AMC</a> remained in the ‘bullish’ territory, with chatter at ‘high’ levels, according ot data from Stocktwits.“The Official Release Party Of A Showgirl” will also play at Cineplex in Canada, Cinepolis and Cinemex in Mexico, beginning at 3 p.m. EDT. AMC will also bring it to theatres in 100 additional countries or more outside of the United States.AMC noted that this was the second collaboration between Swift and AMC Theatres Distribution, which in 2023 launched “The Eras Tour” concert film, which grossed more than $261 million at the global box office, making it the highest-grossing concert film of all time.Swift’s Eras Tour concert was held at various global cities for a span of nearly two years, with the last leg of the show wrapping up in December 2024.&nbsp;A bullish user on Stocktwits noted it has a “swifty effect.” This term has been in use since Swift’s Eras Tour concert, which helped boost consumer spending in economies and also resulted in an increase in traffic at Target stores during the release of copies of her new Eras Tour book and vinyl album.<stembedurl>https://stocktwits.com/Cojax0203/message/629316983</stembedurl>Shares of AMC have declined 37% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/brighthouse-financial-stock-jumps-26-after-this-potential-deal-repor/chD37BKR3TQ">Brighthouse Financial Stock Jumps 26% After This Potential Deal Report: More Details Inside</a>

Taylor Swift attends the 67th Annual GRAMMY Awards on February 02, 2025 in Los Angeles, California. (Photo by Matt Winkelmeyer/Getty Images for The Recording Academy)

AMC Entertainment Stock Is Rising Today And There’s A Taylor Swift Angle – Find Out More

Swift’s 12th studio album, The Life of a Showgirl, is set to drop on October 3, and the movie will also be released on the same day. 

In this photo illustration, the Bloom Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Stock Nearly Doubled In A Month, And It Just Received A Fresh Price Target Hike By Roth Capital – Find Out More

Roth Capital stated that it views Bloom Energy’s current positioning as perhaps the most positive in the company’s history.

Ford Motor Co. (F) is recalling 101,944 vehicles in the U.S., citing concerns that certain door trims may detach while driving, U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said on Friday.The NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V611-3314.pdf">said</a> that the recall involves model year 2016-2019 Taurus vehicles. The driver and front passenger B-Pillar door trim may detach while driving, creating a road hazard and increasing the risk of a crash, the regulator said.As for a solution, Ford dealers will inspect the B-pillar trim and either repair or replace it as necessary, free of cost to the customer. The final remedy is expected to be available by December 2025.Shares of Ford traded 1% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">F stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_10_11_05_AM_png_7c1776a6b4.webp" alt="F's Sentiment Meter and Message Volume as of 10:11 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>F's Sentiment Meter and Message Volume as of 10:11 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user hopes the stock will surpass $12 before the weekend.<stembedurl>https://stocktwits.com/Baseball89/message/629237094</stembedurl>The NHTSA stated that applique detachment may result from the incomplete adhesion of the part to the door sheet metal during installation at the vehicle assembly plant. Customers may notice the B-pillar trim applique separating from the top of the front door when entering or exiting the vehicles, or might hear a rattling noise as they drive.The recall follows the identification of the risk of front door B-pillar trim detachment on a population of model-year 2016-2017 Ford Explorer vehicles. Ford then began to identify potential trim detachment risks on all other Ford and Lincoln vehicle lines and identified several warranty claims citing applique detachment on Taurus vehicles.Ford is aware of 452 warranty claims of the B-pillar appliques detaching from vehicles produced for the U.S. and U.S. Federal territories markets as of September 5, the NHTSA said. However, the company is not aware of any related accidents or injuries.F stock is up 18% this year and approximately 7% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intercure-to-buy-ishi-in-all-stock-transaction/chD3PW9R3TT">InterCure To Buy ISHI In All-Stock Transaction – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford logo seen on a car outside a Ford dealership in Edmonton, AB, Canada, on February 02, 2025. (Photo by Artur Widak/NurPhoto via Getty Images)

Ford Recalls Over 100,000 Taurus Vehicles In US Over Concerns Of Detaching Door Trims 

The driver and front passenger B-Pillar door trim may detach while driving, creating a road hazard and increasing the risk of a crash, the regulator said.

Alphabet’s (GOOG, GOOGL) Google said in a blog post that it was rolling out its artificial intelligence assistant Gemini on its web browser Chrome for Mac and Windows desktop users in the U.S. starting on Thursday.&nbsp;&nbsp;Google stated that it would be made available to businesses in the coming weeks via Google Workspace with enterprise-grade data protections and controls.The company added that it was also bringing Gemini in Chrome to mobile users in the U.S. It noted that a user can activate Gemini when using Chrome on Android and other apps by holding the power button. Google said starting soon, even on iOS, Gemini in Chrome will be built into the app.Retail sentiment on <a href="https://stocktwits.com/symbol/GOOGL">Alphabet</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘normal’ levels, according to data from Stocktwits. Shares of Alphabet were up nearly 1% during midday trading.Google noted that this would help users ask Gemini to clarify complex information on any webpage (or webpages) they are reading. In the coming months, it will introduce agent-based capabilities to Gemini in Chrome. This feature would enable Gemini in Chrome to handle tedious tasks that consume a lot of time, such as booking a haircut or ordering weekly groceries.&nbsp;Google added that it would soon let users use Gemini in Chrome to recall and find a website they had earlier visited by using prompts such as “what was the website that I saw the walnut desk on last week?” or “what was that blog I read on back to school shopping?”Shares of Alphabet have jumped nearly 33% this year and gained about 55% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/meta-chief-product-officer-has-an-interesting-take-on-smart-glasses/chD2cZFR3bV">Meta’s Chief Product Officer Has An Interesting Take On Smart Glasses – More Details Inside</a>

The Gemini app on a smartphone screen, as an index finger approaches the app's icon. (Photo by Matthias Balk/picture alliance via Getty Images)

Google Brings Gemini To Chrome For Users In The US

Google announced that Gemini in Chrome will be made available to businesses in the coming weeks via Google Workspace, offering enterprise-grade data protections and controls.

Darden Restaurants’ (DRI) Chief Financial Officer, Raj Vennam, stated that the company has reaffirmed its full-year earnings per share (EPS) forecast and anticipates the lowest year-over-year EPS growth to occur in the second quarter, driven by a significant increase in beef costs and a measured approach to pricing these costs.“There's been a significant spike in beef costs recently, especially tenders and rib eyes. We don't believe these price levels are sustainable,” Vennam said on a post-earnings call.He added that due to the significant price increase, the company was starting to see “some demand destruction in retail.” “I guess really the big picture, beef is the biggest variable here. The other component here where you're seeing a higher inflation is on seafood, primarily due to the tariffs on shrimp,” stated Vennam.Darden maintained its fiscal 2026 adjusted EPS forecast to be between $10.50 and $10.70. The company now expects annual sales growth to be between 7.5% and 8.5%, compared with the previous forecast of 7% to 8% increase.Retail sentiment on <a href="https://stocktwits.com/symbol/DRI">Darden</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. Shares of the company were down 10% in early trading.<figure class="image"><img style="aspect-ratio:792/97;" src="https://news.stocktwits-cdn.com/DRI_sentiment_png_ac1a6e526e.webp" alt="DRI sentiment.png" width="792" height="97"><figcaption>DRI sentiment and message volume September 18, 2025, as of 11 am ET | Source: Stocktwits</figcaption></figure>The company reported that total sales at Olive Garden increased by 7.6%, driven by strong same-restaurant sales and traffic growth. LongHorn traffic was up about 3.2% for the quarter, and same restaurant sales for the segment rose 5.5%, Darden said.Darden’s first-quarter sales came in at $3.04 billion, in line with analysts’ expectations. Its adjusted EPS was $1.97, compared with estimates of $2.01.Shares of Darden have gained nearly 2% this year and increased by 10% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ftc-sues-ticketmaster-live-nation-over-illegal-ticket-resale-tactics-report/chD2GVlR3bK">FTC Sues Ticketmaster, Live Nation Over ‘Illegal’ Ticket Resale Tactics: Report</a>

The exterior of a LongHorn Steakhouse restaurant is seen on December 19, 2024 in Austin, Texas. 

Darden Flags Q2 Profit Slowdown Amid Surging Beef Costs, CFO Says Price Spike Is Unsustainable

The company now expects annual sales growth to be between 7.5% and 8.5%, compared with the previous forecast of 7% to 8% increase.

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Cracker Barrel Old Country Store (CBRL) shares declined 3% in early trading on Thursday after multiple Wall Street analysts trimmed their price target on the stock, noting a decline in traffic following the company’s controversial logo change in late August.Citigroup lowered the firm's price target on Cracker Barrel to $42 from $47 and maintained a ‘Sell’ rating, according to TheFly. The company reset fiscal 2026 expectations to well below estimates, acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.Cracker Barrel reverted to its old logo in August following a week-long controversy over its new logo that drew outrage from President Donald Trump as well. Last week, the company announced that it would suspend remodeling of restaurants to retain the “Old Timer” logo.Retail sentiment on <a href="https://stocktwits.com/symbol/CBRL">Cracker Barrel</a> dipped to ‘bearish’ from ‘bullish’ territory a day ago, with chatter at ‘high’ levels, according to data from Stocktwits. The retail message count also jumped nearly 500% over 24 hours as of Thursday morning on Stocktwits.<figure class="image"><img style="aspect-ratio:802/87;" src="https://news.stocktwits-cdn.com/CBRL_sentiment_png_30976da71f.webp" alt="CBRL sentiment .png" width="802" height="87"><figcaption>CBRL sentiment and message volume September 18, 2025, as of 10 am ET | Source: Stocktwits</figcaption></figure>Piper Sandler also cut its price target on Cracker Barrel to $49 from $56 and maintained a ‘Neutral’ rating, while Bank of America lowered its price target to $42 from $48 and maintained an ‘Underperform’ rating.Bank of America noted that stronger fiscal fourth-quarter restaurant comparable growth was "overshadowed by the recent uproar" around the company's logo change and store prototype test.CFO Craig Pommells said during the post-earnings call that traffic for the first half of August was down about 1%. Since August 19, the date of the initial logo change, traffic has declined approximately 8%.Cracker Barrel said that it expects fiscal 2026 total revenue to be between $3.35 billion and $3.45 billion, compared with estimates of $3.52 billion, according to data from Fiscal AI.Truist Securities trimmed its price target on Cracker Barrel to $58 from $62 and recommended a buy based on the weakness, citing its view that the core drivers of the brand's turnaround remain intact and that sales may start to recover from the rebranding and the resumption of Fall Menu marketing.Shares of Cracker Barrel have declined by nearly 7% and fallen 20% over the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-ondas-stock-rising-today/chDcxyCR3bO">Why Is Ondas Stock Rising Today?</a>

A Cracker Barrel sign featuring the old logo hangs on the outside of a restaurant on August 21, 2025 in Homestead, Florida. (Photo by Joe Raedle/Getty Images)

Cracker Barrel In Spotlight After Slew Of Price Target Cuts: Citi Says Q1 Began In A ‘Deep Traffic Hole’ Post Logo Change

Citigroup lowered its price target on the stock to $42 from $47, noting that the company reset fiscal 2026 expectations well below estimates, while acknowledging that the first quarter began in a "deep traffic hole" due to the logo mishap.

Shares of GE Healthcare Technologies (GEHC) jumped 1% in the pre-market session on Thursday, following reports that the company is considering options, including the sale of a stake in its China unit.Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-18/ge-healthcare-is-said-to-explore-selling-stake-in-china-business?srnd=homepage-asia">reported</a> on Thursday, citing people familiar with the matter, that the U.S.medical technology company has been working with advisers to evaluate options for the business. A potential transaction may value the China assets at several billion dollars, the report said.However, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary, sources told Bloomberg. According to the report, China is the company’s second-largest market, with approximately 7,000 employees in the region. &nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GEHC">GEHC stock</a> fell from ‘bullish’ to’ neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:928/100;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_083008_png_caa300d3aa.webp" alt="GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="928" height="100"><figcaption>GEHC's Sentiment Meter and Message Volume as of 7:49 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>GE Healthcare was spun off from General Electric in 2023. It delivers advanced technologies, pharmaceutical diagnostics, and AI-powered tools for medical use. According to the company, it has over 200 imaging software applications and treats over a billion patients annually.In February, the company said that its revenue growth in the U.S. in 2024 was partially offset by continued market softness in China. For the second quarter, GE Healthcare reported adjusted earnings per share of $1.06, compared to $1 in the corresponding quarter of 2024, and revenue growth of 3% on a reported basis to $5 billion.GEHC stock is down 2% this year and approximately 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-89bio-stock-nearly-double-in-value/chDcHJIR3bc">Why Did 89bio Stock Nearly Double In Value Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of GE HealthCare Technologies Inc. in front of a screen showing the company's latest stock market chart on July 28, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside

According to a Bloomberg report, no final decision has been made on the timing and size of a potential disposal, and considerations are preliminary.

American Century ETF Trust - Avantis U.S. Equity ETF

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

AVUS
American Century ETF Trust - Avantis U.S. Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AVUS News

AVUS American Century ETF Trust - Avantis U.S. Equity ETF